Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity

[1]  D. Toppmeyer,et al.  Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients , 2014, Front. Oncol..

[2]  C. Henninger,et al.  DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac. , 2013, Biochimica et biophysica acta.

[3]  S. Meikle,et al.  Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. , 2013, European heart journal cardiovascular Imaging.

[4]  B. Kaina,et al.  Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging , 2013, Cell Death and Disease.

[5]  T. Marwick,et al.  Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. , 2012, Journal of the American College of Cardiology.

[6]  B. Kaina,et al.  Rac1 Protein Signaling Is Required for DNA Damage Response Stimulated by Topoisomerase II Poisons* , 2012, The Journal of Biological Chemistry.

[7]  O. Garrone,et al.  Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis , 2012, Cardiovascular Toxicology.

[8]  K. Lackner,et al.  The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. , 2012, Toxicology and applied pharmacology.

[9]  Zengding Zhou,et al.  Guanine-Nucleotide Exchange Factor H1 Mediates Lipopolysaccharide-Induced Interleukin 6 and Tumor Necrosis Factor &agr; Expression in Endothelial Cells Via Activation of Nuclear Factor &kgr;B , 2012, Shock.

[10]  J. DeCara.  Early Detection of Chemotherapy-Related Left Ventricular Dysfunction , 2012, Current Cardiology Reports.

[11]  M. Turgut,et al.  Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[12]  K. Lackner,et al.  Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity , 2011, Cell Death and Disease.

[13]  G. Dorn,et al.  RhoA protects the mouse heart against ischemia/reperfusion injury. , 2011, The Journal of clinical investigation.

[14]  V. Patel,et al.  An evaluation of transmitral and pulmonary venous Doppler indices for assessing murine left ventricular diastolic function. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  J. Liao,et al.  Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[16]  I. Komuro,et al.  Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. , 2009, Journal of molecular and cellular cardiology.

[17]  D. Yellon,et al.  Statins and cardioprotection--more than just lipid lowering? , 2009, Pharmacology & therapeutics.

[18]  H. Kroemer,et al.  Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. , 2009, Cancer research.

[19]  A. Ortiz,et al.  Essential Role of TGF-β/Smad Pathway on Statin Dependent Vascular Smooth Muscle Cell Regulation , 2008, PloS one.

[20]  L. Matsubara,et al.  Anthracycline-induced cardiotoxicity. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[21]  Chao-Po Lin,et al.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. , 2007, Cancer research.

[22]  B. Kaina,et al.  Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide , 2006, British journal of pharmacology.

[23]  P. Hordijk.  Regulation of NADPH Oxidases: The Role of Rac Proteins , 2006, Circulation research.

[24]  J. Elaerts,et al.  Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[25]  S. Lipshultz,et al.  Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies , 2005, British journal of haematology.

[26]  G. Fritz.  HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). , 2005, International journal of oncology.

[27]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[28]  Yi Zheng,et al.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Goppelt‐Struebe,et al.  Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.

[30]  B. Kaina,et al.  Rho GTPases Are Involved in the Regulation of NF-κB by Genotoxic Stress , 2001 .

[31]  E. Voest,et al.  Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. , 2001, European journal of pharmacology.

[32]  J. Bauer,et al.  Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[34]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[35]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[36]  J. Sanderson,et al.  Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. , 1996, European heart journal.

[37]  Michael Merl,et al.  Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: Diastolic versus systolic parameters , 1995, European Journal of Pediatrics.

[38]  A. Hall,et al.  Ras-related GTPases and the cytoskeleton. , 1992, Molecular biology of the cell.

[39]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[40]  C. Henninger,et al.  Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. , 2015, Pharmacological research.

[41]  Huaxi Xu,et al.  Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. , 2013, Cardiovascular research.

[42]  F. Veglia,et al.  Clinical Relevance and Response to Pharmacologic Therapy , 2010 .

[43]  P. Olive.  Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. , 2004, Methods in cell biology.

[44]  L. Lerman,et al.  Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.

[45]  B. Kaina,et al.  Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. , 2001, Experimental cell research.

[46]  S. Giri,et al.  Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. , 1981, The Journal of pharmacology and experimental therapeutics.